Introduction

Examining the outcomes of a phase three trial assessing the effectiveness of Asprin as an adjunct therapy for high-risk non-metastatic breast cancer survivors, revealing no significant differences in survival rates between the Asprin and placebo groups. The accompanying editorial delves into the challenges and implications of negative trial results and considerations such as age dynamics and equity in Asprin usage.